Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years

Becton Dickinson, and Company BDX lowered its fiscal year 2025 guidance and provided an estimated tariff impact on Thursday.The medical device company reported adjusted earnings per share of $3.35, up from$3.17 a year ago. It beat the consensus of $3.28.The company reported first-quarter 2025 sales of$5.27 billion, up 4.5% year-over-year, missing the consensus of $5.35 billion.Becton Dickinson expects fiscal 2025 revenues of$21.8 billion and $21.9 billion. Its previously issued guidance of$21.7 billion  ...